Gilead Sciences (GILD) Cost of Revenue (2009 - 2026)

Gilead Sciences (GILD) has 18 years of Cost of Revenue data on file, last reported at $1.4 billion in Q1 2026.

• Quarterly Cost of Revenue fell 6.17% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 billion (down 1.6% YoY) and the FY2025 annual result came in at $6.2 billion, changed 0.27% from the prior year.
• Cost of Revenue slipped to $1.4 billion in Q1 2026, from $1.6 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $2.1 billion in Q4 2023 to a low of $1.4 billion in Q3 2022.
• A 5-year average of $1.5 billion and a median of $1.5 billion in 2025 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue plunged 46.86% — and 2023, when it jumped 49.71%.
• Tracing GILD's Cost of Revenue over 5 years: stood at $1.4 billion in 2022, then jumped by 49.71% to $2.1 billion in 2023, then retreated by 24.35% to $1.6 billion in 2024, then climbed by 2.72% to $1.6 billion in 2025, then declined by 11.02% to $1.4 billion in 2026.
• The last three Cost of Revenue figures came in at $1.4 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.